van Vollenhoven RF, Morabito LM, Engleman EG, et al. Treatment of systemic lupus erythematosus with dehydroepiandrosterone: 50 patients treated up to 12 months.
J Rheumatol
. 1998;25:285 - 289.
van Vollenhoven RF, Park JL, Genovese MC, et al. A double-blind, placebo-controlled, clinical trial of dehydroepiandrosterone in severe systemic lupus erythematosus.
Lupus.
1999;8:181 - 187.
Mease PJ, Merrill JT, Lahita R, et al. GL701 (prasterone, dehydroepiandrosterone) improves or stabilizes disease activity in systemic lupus erythematosus. Presented at: The Endocrine Society's 82nd Annual Meeting; June 21 - 24, 2000; Toronto, Canada.
Baulieu EE, Thomas G, Legrain S, et al. Dehydroepiandrosterone (DHEA), DHEA sulfate, and aging: contribution of the DHEAge Study to a sociobiomedical issue.
Proc Natl Acad Sci U S A.
2000;97:4279 - 4284.
Labrie F, Diamond P, Cusan L, et al. Effect of 12-month dehydroepiandrosterone replacement therapy on bone, vagina and endometrium in postmenopausal women.
J Clin Endocrinol Metab
. 1997;82:3498 - 3505.
van Vollenhoven RF, Park JL, Genovese MC, et al. A double-blind, placebo-controlled, clinical trial of dehydroepiandrosterone in severe systemic lupus erythematosus.
Lupus.
1999;8:181 - 187.
Lovas K, Gebre-Medhin G, Trovik TS, et al. Replacement of dehydroepiandrosterone in adrenal failure: no benefit for subjective health status and sexuality in a 9-month, randomized, parallel group clinical trial.
J Clin Endocrinol Metab
. 2003;88:1112 - 1118.
Strous RD, Maayan R, Lapidus R, et al. Dehydroepiandrosterone augmentation in the management of negative, depressive, and anxiety symptoms in schizophrenia.
Arch Gen Psychiatry
. 2003;60:133 - 141.
Arlt W, Callies F, van Vlijmen JC, et al. Dehydroepiandrosterone replacement in women with adrenal insufficiency.
N Engl J Med.
1999;341:1013 - 1020.
Hunt PJ, Gurnell EM, Huppert FA, et al. Improvement in mood and fatigue after dehydroepiandrosterone replacement in Addison's disease in a randomized, double blind trial.
J Clin Endocrinol Metab
. 2000;85:4650 - 4656.
Baulieu EE, Thomas G, Legrain S, et al. Dehydroepiandrosterone (DHEA), DHEA sulfate, and aging: contribution of the DHEAge Study to a sociobiomedical issue.
Proc Natl Acad Sci U S A.
2000;97:4279 - 4284.
Morales AJ, Nolan JJ, Nelson JC, et al. Effects of replacement dose of dehydroepiandrosterone in men and women of advancing age.
J Clin Endocrinol Metab
. 1994;78:1360 - 1367.
Flynn MA, Weaver-Osterholtz D, Sharpe-Timms KL, et al. Dehydroepiandrosterone replacement in aging humans.
J Clin Endocrinol Metab
. 1999;84:1527 - 1533.
Reiter WJ, Pycha A, Schatzl G, et al. Dehydroepiandrosterone in the treatment of erectile dysfunction: a prospective double-blind, randomized, placebo-controlled study.
Urology.
1999;53:590 - 595.
Percheron G, Hogrel JY, Denot-Ledunois S, et al. Effect of 1-year oral administration of dehydroepiandrosterone to 60- to 80-year-old individuals on muscle function and cross-sectional area: a double-blind placebo-controlled trial.
Arch Intern Med
. 2003;163:720 - 727.
Wolkowitz OM, Kramer JH, Reus VI, et al. DHEA treatment of Alzheimer's disease: a randomized, double-blind, placebo-controlled study.
Neurology
. 2003;60:1071 - 1076.
Himmel PB, Seligman TM. A pilot study employing dehydroepiandrosterone (DHEA) in the treatment of chronic fatigue syndrome.
J Clin Rheumatol.
1999;5:56 - 59.
Araneo B, Dowell T, Woods ML, et al. DHEAS as an effective vaccine adjuvant in elderly humans. Proof-of-principle studies.
Ann N Y Acad Sci.
1995;774:232 - 248.
Evans TG, Judd ME, Dowell T, et al. The use of oral dehydroepiandrosterone sulfate as an adjuvant in tetanus and influenza vaccination of the elderly.
Vaccine.
1996;14:1531 - 1537.
Araneo B, Daynes R. Dehydroepiandrosterone functions as more than an antiglucocorticoid in preserving immunocompetence after thermal injury.
Endocrinology.
1995;136:393 - 401.
Araneo BA, Shelby J, Li G-Z, et al. Administration of dehydroepiandrosterone to burned mice preserves normal immunologic competence.
Arch Surg.
1993;128:318 - 325.
Klibanski A, Biller BM, Schoenfeld DA, et al. The effects of estrogen administration on trabecular bone loss in young women with anorexia nervosa.
J Clin Endocrinol Metab
. 1995;80:898-904.
Gordon CM, Grace E, Emans SJ. Effects of oral dehydroepiandrosterone on bone density in young women with anorexia nervosa: a randomized trial.
J Clin Endocrinol Metab
. 2002;87:4935 - 4941.
Piketty C, Jayle D, Leplege A, et al. Double-blind placebo-controlled trial of oral dehydroepiandrosterone in patients with advanced HIV disease.
Clin Endocrinol (Oxf).
2001;55:325 - 330.
Rabkin JG, Ferrando SJ, Wagner GJ, et al. DHEA treatment for HIV+ patients: effects on mood, androgenic and anabolic parameters.
Psychoneuroendocrinology.
2000;25:53 - 68.
Regelson W, Kalimi M. Dehydroepiandrosterone (DHEA) - the multifunctional steroid. II. Effects on the CNS, cell proliferation, metabolic and vascular, clinical, and other effects. Mechanism of action?
Ann N Y Acad Sci
. 1994;719:564 - 575.
Regelson W, Loria R, Kalimi M. Dehydroepiandrosterone (DHEA) - the "Mother Steroid." I. Immunologic action.
Ann N Y Acad Sci
. 1994;719:553 - 563.
Brown GA, Vukovich MD, Sharp RL, et al. Effect of oral DHEA on serum testosterone and adaptations to resistance training in young men.
J Appl Physiol
. 1999;87:2274 - 2283.
Wallace MB, Lim J, Cutler A, et al. Effects of dehydroepiandrosterone vs androstenedione supplementation in men.
Med Sci Sports Exerc
. 1999;31:1788 - 1792.
Morales AJ, Haubrich RH, Hwang JY, et al. The effect of six months treatment with a 100 mg daily dose of dehydroepiandrosterone (DHEA) on circulating sex steroids, body composition and muscle strength in age-advanced men and women.
Clin Endocrinol (Oxf)
. 1998;49:421 - 432.
Wolf OT, Neumann O, Hellhammer DH, et al. Effects of a two-week physiological dehydroepiandrosterone substitution on cognitive performance and well-being in healthy elderly women and men.
J Clin Endocrinol Metab
. 1997;82:2363 - 2367.
Barnhart KT, Freeman E, Grisso JA, et al. The effect of dehydroepiandrosterone supplementation to symptomatic perimenopausal women on serum endocrine profiles, lipid parameters, and health-related quality of life.
J Clin Endocrinol Metab.
1999;84:3896 - 3902.
Flynn MA, Weaver-Osterholtz D, Sharpe-Timms KL, et al. Dehydroepiandrosterone replacement in aging humans.
J Clin Endocrinol Metab.
1999;84:1527 - 1533.
van Niekerk JK, Huppert FA, Herbert J. Salivary cortisol and DHEA: association with measures of cognition and well-being in normal older men, and effects of three months of DHEA supplementation.
Psychoneuroendocrinology.
2001;26:591 - 612.
Kudielka BM, Hellhammer J, Hellhammer DH, et al. Sex differences in endocrine and psychological responses to psychosocial stress in healthy elderly subjects and the impact of a 2-week dehydroepiandrosterone treatment.
J Clin Endocrinol Metab.
1998;83:1756 - 1761.
Arlt W, Callies F, Koehler I, et al. Dehydroepiandrosterone supplementation in healthy men with an age-related decline of dehydroepiandrosterone secretion.
J Clin Endocrinol Metab.
2001;86:4686 - 4692.
Hackbert L, Heiman JR. Acute dehydroepiandrosterone (DHEA) effects on sexual arousal in postmenopausal women.
J Womens Health Gend Based Med
. 2002;11:155 - 162.
Chang DM, Lan JL, Lin HY, et al. Dehydroepiandrosterone treatment of women with mild-to-moderate systemic lupus erythematosus: A multicenter randomized, double-blind, placebo-controlled trial.
Arthritis Rheum
. 2002;46:2924 - 2927.
Barrett-Connor E, Goodman-Gruen D. Dehydroepiandrosterone sulfate does not predict cardiovascular death in postmenopausal women. The Rancho Bernardo Study.
Circulation.
1995;91:1757 - 1760.
Herrington DM, Nanjee N, Achuff SC, et al. Dehydroepiandrosterone and cardiac allograft vasculopathy.
J Heart Lung Transplant.
1996;15:88 - 93.
Jesse RL, Loesser K, Eich DM, et al. Dehydroepiandrosterone inhibits human platelet aggregation
in vitro
and
in vivo.Ann N Y Acad Sci.
1995;774:281 - 290.
Barrett-Connor E, Khaw K-T, Yen SSC. A prospective study of dehydroepiandrosterone sulfate, mortality, and cardiovascular disease.
N Engl J Med.
1986;315:1519 - 1524.
Nafziger AN, Herrington DM, Bush TL. Dehydroepiandrosterone and dehydroepiandrosterone sulfate: their relation to cardiovascular disease.
Epidemiol Rev.
1991;13:267 - 293.
Barrett-Connor E, Khaw K-T. Absence of an inverse relation of dehydroepiandrosterone sulfate with cardiovascular mortality in postmenopausal women [letter].
N Engl J Med.
1987;317:711.
Vogiatzi MG, Boeck MA, Vlachopapadopoulou E, et al. Dehydroepiandrosterone in morbidly obese adolescents: effects on weight, body composition, lipids, and insulin resistance.
Metabolismo.
1996;45:1011 - 1015.
Mease PJ, Merrill JT, Lahita R, et al. GL701 (prasterone, dehydroepiandrosterone) improves or stabilizes disease activity in systemic lupus erythematosus. Presented at: The Endocrine Society's 82nd Annual Meeting; June 21 - 24, 2000; Toronto, Canada.
van Vollenhoven RF, Morabito LM, Engleman EG, et al. Treatment of systemic lupus erythematosus with dehydroepiandrosterone: 50 patients treated up to 12 months.
J Rheumatol
. 1998;25:285 - 289.
van Vollenhoven RF, Park JL, Genovese MC, et al. A double-blind, placebo-controlled, clinical trial of dehydroepiandrosterone in severe systemic lupus erythematosus.
Lupus.
1999;8:181 - 187.
Robinzon B, Cutulo M. Should dehydroepiandrosterone replacement therapy be provided with glucocorticoids?
Reumatología (Oxford).
1999;38:488 - 495.
van Vollenhoven RF, Park JL, Genovese MC, et al. A double-blind, placebo-controlled, clinical trial of dehydroepiandrosterone in severe systemic lupus erythematosus.
Lupus.
1999;8:181 - 187.
Baulieu EE, Thomas G, Legrain S, et al. Dehydroepiandrosterone (DHEA), DHEA sulfate, and aging: contribution of the DHEAge Study to a sociobiomedical issue.
Proc Natl Acad Sci U S A.
2000;97:4279 - 4284.
Labrie F, Diamond P, Cusan L, et al. Effect of 12-month dehydroepiandrosterone replacement therapy on bone, vagina and endometrium in postmenopausal women.
J Clin Endocrinol Metab
. 1997;82:3498 - 3505.
van Vollenhoven RF, Park JL, Genovese MC, et al. A double-blind, placebo-controlled, clinical trial of dehydroepiandrosterone in severe systemic lupus erythematosus.
Lupus.
1999;8:181 - 187.
Greendale GA, Edelstein S, Barrett-Connor E. Endogenous sex steroids and bone mineral density in older women and men: the Rancho Bernardo Study.
J Bone Miner Res.
1997;12:1833 - 1843.
Arlt W, Callies F, van Vlijmen JC, et al. Dehydroepiandrosterone replacement in women with adrenal insufficiency.
N Engl J Med.
1999;341:1013 - 1020.
Hunt PJ, Gurnell EM, Huppert FA, et al. Improvement in mood and fatigue after dehydroepiandrosterone replacement in Addison's disease in a randomized, double blind trial.
J Clin Endocrinol Metab
. 2000;85:4650 - 4656.
Baulieu EE, Thomas G, Legrain S, et al. Dehydroepiandrosterone (DHEA), DHEA sulfate, and aging: contribution of the DHEAge Study to a sociobiomedical issue.
Proc Natl Acad Sci U S A.
2000;97:4279 - 4284.
Reiter WJ, Pycha A, Schatzl G, et al. Dehydroepiandrosterone in the treatment of erectile dysfunction: a prospective, double-blind, randomized, placebo-controlled study.
Urology.
1999;53:590 - 595.
Brown GA, Vukovich MD, Sharp RL, et al. Effect of oral DHEA on serum testosterone and adaptations to resistance training in young men.
J Appl Physiol.
1999;87:2274 - 2283.
Wallace MB, Lim J, Cutler A, et al.
Effects of dehydroepiandrosterone vs androstenedione supplementation in men.
Med Sci Sports Exerc.
1999;31:1788 - 1792.
Morales AJ, Haubrich RH, Hwang JY, et al. The effect of six months treatment with a 100 mg daily dose of dehydroepiandrosterone (DHEA) on circulating sex steroids, body composition and muscle strength in age-advanced men and women.
Clin Endocrinol (Oxf).
1998;49:421 - 432.
van Vollenhoven RF, Morabito LM, Engleman EG, et al. Treatment of systemic lupus erythematosus with dehydroepiandrosterone: 50 patients treated up to 12 months.
J Rheumatol
. 1998;25:285 - 289.
Casson PR, Santoro N, Elkind-Hirsch K, et al. Postmenopausal dehydroepiandrosterone administration increases free insulin-like growth factor-I and decreases high-density lipoprotein: a six-month trial.
Fertil Steril.
1998;70:107 - 110.
Mease PJ, Merrill JT, Lahita R, et al. GL701 (prasterone, dehydroepiandrosterone) improves or stabilizes disease activity in systemic lupus erythematosus. Presented at: The Endocrine Society's 82nd Annual Meeting; June 21 - 24, 2000; Toronto, Canada.
Mease PJ, Merrill JT, Lahita R, et al. GL701 (prasterone, dehydroepiandrosterone) improves or stabilizes disease activity in systemic lupus erythematosus. Presented at: The Endocrine Society's 82nd Annual Meeting; June 21 - 24, 2000; Toronto, Canada.
van Vollenhoven RF, Engleman EG, McGuire JL. Dehydroepiandrosterone in systemic lupus erythematosus. Results of a double-blind, placebo-controlled, randomized clinical trial.
Arthritis Rheum
. 1995;38:1826 - 1831.
Gatto V, Aragno M, Gallo M, et al. Dehydroepiandrosterone inhibits the growth of DMBA-induced rat mammary carcinoma via the androgen receptor.
Oncol Rep
. 1998;5:241 - 243.
Orner GA, Mathews C, Hendricks JD, et al. Dehydroepiandrosterone is a complete hepatocarcinogen and potent tumor promoter in the absence of peroxisome proliferation in rainbow trout.
Carcinogenesis
. 1995;16:2893 - 2898.
Shibata MA, Hasegawa R, Imaida K, et al. Chemoprevention by dehydroepiandrosterone and indomethacin in a rat multiorgan carcinogenesis model.
Cancer Res
. 1995;55:4870 - 4874.
Simile M, Pascale RM, De Miglio MR, et al. Inhibition by dehydroepiandrosterone of growth and progression of persistent liver nodules in experimental rat liver carcinogenesis.
Int J Cancer
. 1995;62:210 - 215.
Barrett-Connor E, Friedlander NJ, Khaw K-T. Dehydroepiandrosterone sulfate and breast cancer risk.
Cáncer Res.
1990;50:6571 - 6574.
Helzlsouer KJ, Alberg AJ, Gordon GB, et al. Serum gonadotropins and steroid hormones and the development of ovarian cancer.
JAMA.
1995;274:1926 - 1930.
Wolf OT, Naumann E, Hellhammer DH, et al. Effects of dehydroepiandrosterone replacement in elderly men on event-related potentials, memory, and well-being.
J Gerontol.
1998;53:M385-M390.
Kahn AJ, Haloran B. Dehydroepiandrosterone supplementation and bone turnover in middle-aged to elderly men.
J Clin Endocrinol Metab.
2002;87:1544-1549.
Meston CM, Heiman JR. Acute dehydroepiandrosterone effects on sexual arousal in premenopausal women.
J Sex Marital Ther.
2002;28:53-60.
Último revisado Septiembre 2003 por EBSCO CAM Medical Review Board
La información aquí suministrada complementa la atención recibida por su médico. De ninguna forma intenta sustituir el consejo de un professional medico. LLAME A SU MEDICO DE INMEDIATO SI PIENSA QUE PODRIA TENER UNA EMERGENCIA. Siempre busque consejo médico antes de comenzar un nuevo tratamiento o si tiene preguntas sobre una condición médica.
Copyright © EBSCO Publishing. All rights reserved.